Cargando…

Revealing the combined roles of Aβ and tau in Alzheimer’s disease via a pathophysiological activity decoder

Neuronal dysfunction and cognitive deterioration in Alzheimer’s disease (AD) are likely caused by multiple pathophysiological factors. However, evidence in humans remains scarce, necessitating improved non-invasive techniques and integrative mechanistic models. Here, we introduce personalized brain...

Descripción completa

Detalles Bibliográficos
Autores principales:	Sanchez-Rodriguez, Lazaro M., Bezgin, Gleb, Carbonell, Felix, Therriault, Joseph, Fernandez-Arias, Jaime, Servaes, Stijn, Rahmouni, Nesrine, Tissot, Cecile, Stevenson, Jenna, Karikari, Thomas K., Ashton, Nicholas J., Benedet, Andréa L., Zetterberg, Henrik, Blennow, Kaj, Triana-Baltzer, Gallen, Kolb, Hartmuth C., Rosa-Neto, Pedro, Iturria-Medina, Yasser
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Cold Spring Harbor Laboratory 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10370127/ https://www.ncbi.nlm.nih.gov/pubmed/37502947 http://dx.doi.org/10.1101/2023.02.21.529377

Ejemplares similares

A two-step workflow based on plasma p-tau217 to screen for amyloid β positivity with further confirmatory testing only in uncertain cases
por: Brum, Wagner S., et al.
Publicado: (2023)

Association of Phosphorylated Tau Biomarkers With Amyloid Positron Emission Tomography vs Tau Positron Emission Tomography
por: Therriault, Joseph, et al.
Publicado: (2022)

Astrocyte reactivity influences the association of amyloid-β and tau biomarkers in preclinical Alzheimer’s disease
por: Pascoal, Tharick, et al.
Publicado: (2023)

Medial temporal tau predicts memory decline in cognitively unimpaired elderly
por: Kwan, Angela T H, et al.
Publicado: (2022)

Association of plasma P-tau181 with memory decline in non-demented adults
por: Therriault, Joseph, et al.
Publicado: (2021)

Comparing tau status determined via plasma pTau181, pTau231 and [(18)F]MK6240 tau-PET
por: Tissot, Cécile, et al.
Publicado: (2022)

Astrocyte reactivity influences amyloid-β effects on tau pathology in preclinical Alzheimer’s disease
por: Bellaver, Bruna, et al.
Publicado: (2023)

Biomarker modeling of Alzheimer’s disease using PET-based Braak staging
por: Therriault, Joseph, et al.
Publicado: (2022)

14-3-3 [Formula: see text] -reported early synaptic injury in Alzheimer’s disease is independently mediated by sTREM2
por: Woo, Marcel S., et al.
Publicado: (2023)

Astrocyte biomarker signatures of amyloid-β and tau pathologies in Alzheimer’s disease
por: Ferrari-Souza, João Pedro, et al.
Publicado: (2022)

Diagnostic accuracy of the plasma ALZpath pTau217 immunoassay to identify Alzheimer’s disease pathology
por: Ashton, Nicholas J., et al.
Publicado: (2023)

Plasma levels of phosphorylated tau 181 are associated with cerebral metabolic dysfunction in cognitively impaired and amyloid-positive individuals
por: Lussier, Firoza Z, et al.
Publicado: (2021)

APOEε4 associates with microglial activation independently of Aβ plaques and tau tangles
por: Ferrari-Souza, João Pedro, et al.
Publicado: (2023)

Amyloid beta plaque accumulation with longitudinal [18F]AZD4694 PET
por: Therriault, Joseph, et al.
Publicado: (2023)

The Use of Tau PET to Stage Alzheimer Disease According to the Braak Staging Framework
por: Macedo, Arthur C., et al.
Publicado: (2023)

Head-to-head comparison of 10 plasma phospho-tau assays in prodromal Alzheimer’s disease
por: Janelidze, Shorena, et al.
Publicado: (2022)

Development and validation of a high‐sensitivity assay for measuring p217+tau in plasma
por: Triana‐Baltzer, Gallen, et al.
Publicado: (2021)

Plasma pTau181 predicts cortical brain atrophy in aging and Alzheimer’s disease
por: Tissot, Cécile, et al.
Publicado: (2021)

Neuropsychiatric Symptoms and Microglial Activation in Patients with Alzheimer Disease
por: Schaffer Aguzzoli, Cristiano, et al.
Publicado: (2023)

Editorial: Blood Biomarkers of Neurodegenerative Diseases
por: Karikari, Thomas K., et al.
Publicado: (2022)

The accuracy and robustness of plasma biomarker models for amyloid PET positivity
por: Benedet, Andréa L., et al.
Publicado: (2022)

Development and Validation of a High Sensitivity Assay for Measuring p217 + tau in Cerebrospinal Fluid
por: Triana-Baltzer, Gallen, et al.
Publicado: (2020)

Verbal memory formation across PET-based Braak stages of tau accumulation in Alzheimer’s disease
por: Fernández Arias, Jaime, et al.
Publicado: (2023)

Antibody-free measurement of cerebrospinal fluid tau phosphorylation across the Alzheimer’s disease continuum
por: Gobom, Johan, et al.
Publicado: (2022)

Bayesian workflow for the investigation of hierarchical classification models from tau-PET and structural MRI data across the Alzheimer’s disease spectrum
por: Belasso, Clyde J., et al.
Publicado: (2023)

Impact of long- and short-range fibre depletion on the cognitive deficits of fronto-temporal dementia
por: Savard, Melissa, et al.
Publicado: (2022)

Mass spectrometric simultaneous quantification of tau species in plasma shows differential associations with amyloid and tau pathologies
por: Montoliu-Gaya, Laia, et al.
Publicado: (2023)

Hippocampal subfield associations with memory depend on stimulus modality and retrieval mode
por: Aumont, Etienne, et al.
Publicado: (2023)

Diagnostic and prognostic performance to detect Alzheimer’s disease and clinical progression of a novel assay for plasma p-tau217
por: Groot, Colin, et al.
Publicado: (2022)

Correction: Diagnostic and prognostic performance to detect Alzheimer’s disease and clinical progression of a novel assay for plasma p-tau217
por: Groot, Colin, et al.
Publicado: (2022)

Association between polygenic risk score of Alzheimer’s disease and plasma phosphorylated tau in individuals from the Alzheimer’s Disease Neuroimaging Initiative
por: Zettergren, Anna, et al.
Publicado: (2021)

A three‐range approach enhances the prognostic utility of CSF biomarkers in Alzheimer's disease
por: Brum, Wagner S., et al.
Publicado: (2022)

Profiling classical neuropsychiatric biomarkers across biological fluids and following continuous lumbar puncture: A guide to sample type and time
por: Triana-Baltzer, Gallen, et al.
Publicado: (2022)

Differences between blood and cerebrospinal fluid glial fibrillary Acidic protein levels: The effect of sample stability
por: Simrén, Joel, et al.
Publicado: (2022)

Plasma biomarkers for neurodegenerative disorders: ready for prime time?
por: Balogun, Wasiu G., et al.
Publicado: (2023)

Cerebrospinal fluid p-tau231 as an early indicator of emerging pathology in Alzheimer's disease
por: Ashton, Nicholas J., et al.
Publicado: (2022)

Integrated transcriptomic and neuroimaging brain model decodes biological mechanisms in aging and Alzheimer’s disease
por: Adewale, Quadri, et al.
Publicado: (2021)

Spitting image: can saliva biomarkers reflect Alzheimer's disease?
por: Ashton, Nicholas J., et al.
Publicado: (2021)

The Association of Age-Related and Off-Target Retention with Longitudinal Quantification of [(18)F]MK6240 Tau PET in Target Regions
por: Tissot, Cécile, et al.
Publicado: (2023)

Commentary: Global, regional, and national burden of neurological disorders during 1990–2015: a systematic analysis for the Global Burden of Disease Study 2015
por: Karikari, Thomas K., et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_hu60cpodk80tgvrtkuequc5f9c